Moderna (MRNA) shares have surged significantly over the past year, prompting a critical re-evaluation of whether its current valuation is supported by underlying sales performance or merely recent momentum. The article highlights that while news regarding mRNA products, such as the mFlusiva flu vaccine launch and patent developments in Europe, influences investor sentiment, the core question remains if the stock price can be justified by revenue outlooks. Simply Wall St analysis indicates that Price-to-Sales (P/S) is the most relevant metric for Moderna given its current loss-making status. The company trades at a P/S ratio of 32.7x, which represents a substantial premium compared to the biotech industry average of 12.8x and peer group averages around 6.8x. This valuation implies investors are paying a high price for every dollar of recent revenue. Valuation models suggest a fair multiple significantly lower than the current market price, largely due to penalties applied for recent losses and perceived risks surrounding future product sales. Community narratives on the platform have identified scenarios where Moderna could be considered 306% overvalued, citing bearish views that post-data share price reactions imply overly broad adoption of its intismeran across multiple tumor types.